Skip to main content
. 2022 Jun 17;48(7):899–909. doi: 10.1007/s00134-022-06745-7

Table 2.

Primary and secondary endpoints

Tα1 group
(N = 254)
Placebo group
(N = 254)
Risk difference
(95% CI)
p value
Primary endpoint
IPN during the index admission, (n, %) 40 (15.7) 46 (18.1) − 2.36 (− 7.41, 5.07) 0.48
Secondary endpoints*
New-onset organ failure 27 (10.6) 38 (15) − 4.26 (− 8.18, 1.93) 0.15
Respiratory, (n, %) 9 (3.5) 17 (6.7) − 3.15 (− 5.08, 1.08) 0.11
Renal, (n, %) 10 (3.9) 7 (2.8) 1.25 (− 1.19, 7.48) 0.43
Cardiovascular, (n, %) 14 (5.5) 20 (7.9) − 2.33 (− 5.00, 2.82) 0.30
Mortality (n, %) 18 (7.1) 22 (8.7) − 1.55 (− 4.73, 4.21) 0.52
90-Day mortality (n, %) 23 (9.1) 23 (9.1) 0.03 (− 3.79, 6.63) 0.99
IPN within 90 days after randomisation (n, %) 57 (22.4) 65 (25.6) − 3.25 (− 9.18, 4.83) 0.39
Bleeding, (n, %) 16 (6.3) 9 (3.5) 2.80 (− 0.69, 10.53) 0.15
Positive blood culture (n, %) 18 (7.1) 25 (9.8) − 2.73 (− 5.85, 2.83) 0.27
Gastrointestinal fistula, (n, %) 5 (2) 6 (2.4) − 0.41 (− 1.76, 3.91) 0.75
Length of ICU stay, mean (SD), d 14.4 (16.2) 13.6 (16.4) 0.75 (− 2.07, 3.57) 0.60
Length of hospital stay, mean (SD), d 21.0 (21.3) 20.5 (20) 0.46 (− 3.12, 4.03) 0.80
In-hospital cost, mean (SD), Kyuan 143 (177) 138 (206) 5 (− 28, 38) 0.77
Use of invasive interventions
Requiring catheter drainage (n, %)# 36 (14.2) 39 (15.4) − 1.27 (− 6.08, 6.02) 0.69
Requiring MI debridement (n, %)** 17 (6.7) 12 (4.7) 1.96 (− 1.44, 8.91) 0.34
Requiring open surgery (n, %) 8 (3.1) 5 (2) 1.14 (− 0.93, 7.37) 0.41
Number of procedures in patients requiring invasive interventions during the index admission
Number of catheter drainage procedures, median (IQR)+ 2.5 (1–4) 2 (1–3) 0.14 (− 0.58, 0.85) 0.71
Number of MI debridement procedures, median (IQR)++ 3 (2–6) 4 (3–5) − 0.52 (− 1.95, 0.91) 0.48

CI denotes confidential interval. IPN denotes infected pancreatic necrosis. ICU denotes intensive care unit. MI denotes minimally invasive. *All secondary endpoints were registered during the index admission unless otherwise specified; # both percutaneous and transluminal drainage included; **27 patients underwent exclusive percutaneous surgical MI debridement, one patient underwent exclusive endoscopic transluminal debridement, and one combined; + only patients undergoing catheter drainage procedures are included; ++ only patients undergoing MI debridement procedures are included